BNTX - Spark Newswire

3 minute read

News

BioNTech Announced First Patient Dosed in Phase 2 Clinical Trial of mRNA-based BNT111 in Patients with Advanced Melanoma

June 18, 5:25 AM

BioNTech SE (NASDAQ: BNTX) announced today that the first patient has been treated in its BNT111 Phase 2 cancer vaccine trial (2020-002195-12; NCT04526899).

BNTX

2 minute read

Mayo Clinic, nference AI Analysis Find No Real-World Link Between COVID-19 Shots And Clots

By Vandana Singh

June 17, 2:20 PM

A new study from the artificial intelligence (AI)-driven health technology company, nference, and the Mayo Clinic,

BNTX

1 minute read

Biden Administration Devotes Over $3.2B For Development Of Oral Antiviral Therapies For COVID-19: CNBC

By Vandana Singh

June 17, 2:12 PM

Officials on Thursday announced that the Biden Administration plans to invest more than $3.2 billion in developing antiviral medicines to…

BNTX

2 minute read

Tesla-Backed CureVac Plunges On Underwhelming COVID-19 Vaccine Efficacy Data

By Shanthi Rexaline

June 17, 5:07 AM

German vaccine developer, CureVac N.V. (NASDAQ: CVAC), may not be as fortunate as its domestic peer BioNTech SE (NASDAQ:

BNTX

7 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For June 16, 2021

By Benzinga Insights

June 16, 10:05 AM

AEE

1 minute read

Redburn Partners Downgrades BioNTech to Sell

By Benzinga Newsdesk

June 16, 6:51 AM

Redburn Partners analyst Simon Baker downgrades BioNTech (NASDAQ:BNTX) from Neutral to Sell.

BNTX

4 minute read

Novavax Vs. Pfizer Vs. Moderna: How COVID-19 Vaccines Stack Up

By Shanthi Rexaline

June 14, 2:45 PM

It was "better late than never" for Novavax, Inc. (NASDAQ: NVAX), as the biopharma finally got around to announcing interim results from the U.S. and Mexico leg of the Phase 3 study of NVX-CoV2371, its vaccine candidate against the novel coronavirus.

BNTX